Literature DB >> 8566206

Ontogeny of human striatal DARPP-32 neurons in fetuses and following xenografting to the adult rat brain.

S Naimi1, R Jeny, P Hantraye, M Peschanski, D Riche.   

Abstract

After a number of reports indicating positive clinical outcome of intrastriatal transplantation of fetal ventral mesencephalic tissue into patients with Parkinson's disease, the time may have come to consider the possibility of using this technique to treat patients with Huntington's disease. On the basis of the available literature, the Network of European CNS Transplantation and Restoration has established a program aiming at defining the optimal conditions for such clinical trials. The present study, conducted within this framework, pursued the goal of providing information concerning the period of striatal neuronal ontogeny in humans, taking into account the technical and legal requirements imposed by the clinical procedure of neural transplantation using human tissue. On this basis, it aimed at establishing a reliable dissecting method for the intrastriatal grafting of human fetal striatal neurons. The ontogeny of medium-spiny neurons within the developing striatum was first studied in a series of human fetal brains, 5 to 10 weeks postconception, using immunocytochemical detection of DARPP-32. Immunoreactive neurons were observed in fetuses at 7 weeks of age and older. They were mostly localized in clusters, packed in the lateral ganglionic eminence. Over a 2-week-long period, DARPP-32 neurons increased in number. Their morphology remained poorly differentiated, however, with small cell bodies, few branched dendrites, and variable intensity of immunostaining. Based on these findings, selective dissection of the lateral ganglionic eminence was carried out. This tissue was stereotaxically implanted into the striatum of immunosuppressed adult rats previously lesioned. Two months postgrafting, DARPP-32 neurons were observed as discrete patches, embedded within areas of essentially DARPP-32-negative tissue. Up to 2 months after grafting, neurons remained poorly differentiated in general, with only a few neurons exhibiting a dense immunoreactivity and long processes. These results indicate that striatal DARPP-32-immunoreactive neurons are present in the lateral ganglionic eminence in fetuses as soon as 7 weeks postconception. The striatal tissue can be dissected out and successfully transplanted. Within the grafts, neuronal differentiation appears to be a very long process, suggesting that many months might be necessary for these neurons to become functionally integrated into an adult host brain.

Entities:  

Mesh:

Year:  1996        PMID: 8566206     DOI: 10.1006/exnr.1996.0002

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  8 in total

Review 1.  Cell therapy in Huntington's disease.

Authors:  Stephen B Dunnett; Anne E Rosser
Journal:  NeuroRx       Date:  2004-10

2.  Human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges.

Authors:  Camille Nicoleau; Pedro Viegas; Marc Peschanski; Anselme L Perrier
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

3.  Dopaminergic innervation of striatal grafts placed into different sites of normal striatum: differences in the tyrosine hydroxylase immunoreactive growth pattern.

Authors:  L Björklund; I Strömberg
Journal:  Exp Brain Res       Date:  1997-01       Impact factor: 1.972

4.  Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum.

Authors:  Igor Nasonkin; Vasiliki Mahairaki; Leyan Xu; Glen Hatfield; Brian J Cummings; Charles Eberhart; David K Ryugo; Dragan Maric; Eli Bar; Vassilis E Koliatsos
Journal:  Stem Cells       Date:  2009-10       Impact factor: 6.277

5.  Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration.

Authors:  F Cicchetti; S Saporta; R A Hauser; M Parent; M Saint-Pierre; P R Sanberg; X J Li; J R Parker; Y Chu; E J Mufson; J H Kordower; T B Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-20       Impact factor: 11.205

6.  Neo-vascularization of the stroke cavity by implantation of human neural stem cells on VEGF-releasing PLGA microparticles.

Authors:  Ellen Bible; Omar Qutachi; David Y S Chau; Morgan R Alexander; Kevin M Shakesheff; Michel Modo
Journal:  Biomaterials       Date:  2012-07-18       Impact factor: 15.304

7.  Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss.

Authors:  Rahasson R Ager; Joy L Davis; Andy Agazaryan; Francisca Benavente; Wayne W Poon; Frank M LaFerla; Mathew Blurton-Jones
Journal:  Hippocampus       Date:  2015-01-08       Impact factor: 3.899

8.  Human neural stem cell transplantation into the corpus callosum of Alzheimer's mice.

Authors:  Lisa M McGinley; Osama N Kashlan; Kevin S Chen; Elizabeth S Bruno; John M Hayes; Carey Backus; Seth Feldman; Bader N Kashlan; Karl Johe; Eva L Feldman
Journal:  Ann Clin Transl Neurol       Date:  2017-08-18       Impact factor: 4.511

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.